NJ-SOLIDIA-TECHNOLOGIES
15.10.2020 15:02:08 CEST | Business Wire | Press release
Solidia Technologies® CEO Tom Schuler shared the possibility of turning Solidia Concrete into a carbon sink for the planet during his TED Talk at TED and Future Stewards’ Global Countdown Launch. Tom was invited to "The Countdown," a call to action on climate change, to explain how cement and concrete contribute to the global carbon challenge and the potential impact of new production technologies for Solidia Cement™ and Solidia Concrete™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005299/en/
"To address global warming, innovation in both cement production and carbon utilization are absolutely essential," said Tom. "Our new technology for ready-mix concrete is currently being tested for infrastructure applications. And we have already pushed our research beyond that with a technology that enables concrete to become a carbon sink; that means we consume more carbon dioxide (CO2 ) than we emit during production."
Outlining the issue, he explained how concrete contributes to the global carbon challenge because it is made with cement. "For every ton of cement produced, about a ton of CO2 is released into the atmosphere. As a result, the cement industry is the second largest industrial emitter of CO2 , responsible for about eight percent of global emissions."
By changing the chemistry of cement, Solidia both lowers emissions at the cement plant and consumes CO2 in the production of concrete. "Our cement reacts with CO2 instead of water. During curing, the chemical reaction with our cement breaks apart the CO2 molecules and captures the carbon to make limestone that glues the concrete together.”
For production of precast concrete that is cured in kilns, he explained: “When you combine the emissions reduction during cement production with CO2 consumption during curing, we reduce cement’s carbon footprint by up to 70%.”
Describing the different carbon delivery system developed for ready-mix, he added: "Since we can’t use CO2 gas at a construction site, we had to introduce it into our concrete in solid or liquid form. We are partnering with companies that are turning waste CO2 into a family of chemicals, like oxalic or even citric acid – the same one in orange juice. We use these acids to react with our cement and pack in as much as four times more carbon, resulting in carbon-negative concrete.”
Citing the potential impact, Tom explained: “That means that, in just a few hours, one kilometer of road could permanently consume the same amount of CO2 that nearly 100,000 trees absorb in one year. Thanks to chemistry and waste CO2 , we have the potential to transform concrete – the second most utilized material on the planet – into a carbon sink for the planet.”
About Solidia Technologies®
Based in Piscataway, N.J. (USA), Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to create superior and sustainable building and construction materials. At scale each year, Solidia can eliminate at least 1.5 gigatonnes of CO₂, save three trillion liters of fresh water, reduce energy consumption equal to ~260 million barrels of oil, and eliminate 100 million tonnes of concrete landfill waste, while engaging industry in a rapid, globally scalable response to some of the greatest threats facing people and planet. Solidia’s investors include Kleiner Perkins , Bright Capital , BASF , BP , Lafarge Holcim , Total Energy Ventures , Oil and Gas Climate Initiative (OGCI) Climate Investments , Air Liquide , Bill Joy and other private investors. Honors include: the 2020, 2019 and 2014 Global Cleantech 100 ; a 2020 and 2014 Best Place to Work in NJ ; 2020, 2019 and 2018 BP Advancing Low Carbon accreditation; the 2019 Solar Impulse 1000 Efficient Solutions ; 2017 ERA Grand Challenge (formerly CCEMC) finalist; 2016 Sustainia 100 ; 2015 NJBiz Business of the Year; 2014 CCEMC Grand Challenge finalist; 2013 R&D Top 100 ; 2013 Katerva Award finalist; and MIT’s Climate CoLab shortlist. Follow Solidia on LinkedIn , Instagram , Twitter , and YouTube .
About TED
TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily , available on all podcast platforms.
Follow TED on Twitter , Facebook , Instagram and on LinkedIn . Connect at Countdown@ted.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release
Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release
Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release
Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release
Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
